SCYNEXIS, Inc. Payments to Acquire Investments
SCYNEXIS, Inc. (SCYX) reported Payments to Acquire Investments of $27.38 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2022-11-09
- 2022-09-30: Payments to Acquire Investments 9 month $27.38M.
| Period end | Payments to Acquire Investments 9 month |
|---|---|
| 2022-09-30 | $27.38M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |